Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort study

Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort study

Objectives Fostemsavir is a novel attachment inhibitor used with other antiretrovirals in heavily treatment‐experienced (HTE) adults with multidrug‐resistant HIV‐1. Real‐world immunological and virological responses were assessed in individuals starting fostemsavir in the OPERA cohort. Methods Among...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:HIV medicine 2025-01, Vol.26 (1), p.17-25
Hauptverfasser: Hsu, Ricky K., Brunet, Laurence, Lackey, Philip C., Pierone, Gerald, Levis, Brooke, Fusco, Jennifer S., Henegar, Cassidy, Vannappagari, Vani, Clark, Andrew, Fusco, Gregory P.
Format: Artikel
Sprache:eng
Schlagworte:
Adults
Antiviral agents
CD4 antigen
cohort
Fostemsavir
heavily treatment experienced
HIV
Human immunodeficiency virus
Immune response
immunological response
Immunology
Multidrug resistance
Original
virological effectiveness
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives Fostemsavir is a novel attachment inhibitor used with other antiretrovirals in heavily treatment‐experienced (HTE) adults with multidrug‐resistant HIV‐1. Real‐world immunological and virological responses were assessed in individuals starting fostemsavir in the OPERA cohort. Methods Among adults with HIV‐1 starting fostemsavir between 2 July 2020 and 1 September 2022, 6‐month and 12‐month changes in CD4 T‐cell count and CD4%, and maintenance/achievement of viral load (VL)
ISSN:1464-2662
1468-1293
1468-1293
DOI:10.1111/hiv.13700